Where Are We Going with Sentinel Lymph Node Mapping in Gynecologic Cancers?

Area of Science:

• Gynecologic Oncology
• Surgical Pathology
• Cancer Staging

Background:

• Sentinel lymph node (SLN) mapping is a standard diagnostic procedure for lymphatic assessment in early-stage gynecologic malignancies.
• Accurate lymphatic staging is critical for treatment planning and improving patient outcomes.

Purpose of the Study:

• To review current data on the utility and application of SLN mapping in the management of gynecologic cancers.
• To emphasize the role of SLN mapping in reducing patient morbidity while maintaining diagnostic accuracy.

Main Methods:

• Review of recent clinical studies and trials focusing on SLN mapping in endometrial, cervical, and vulvar cancers.
• Analysis of updated National Comprehensive Cancer Network (NCCN) guidelines incorporating SLN mapping.

Main Results:

• SLN mapping is confirmed as safe and effective for high-risk endometrial cancer patients.
• The LACC Trial raises questions about SLN mapping validity with minimally invasive surgery in cervical cancer.
• Ongoing trials (e.g., GROINS-V-II) evaluate SLN metastasis size thresholds for adjuvant therapy in vulvar cancer.
• NCCN guidelines now include SLN mapping for endometrial, cervical, and vulvar malignancies.
• SLN mapping demonstrates reduced morbidity with high detection rates for lymphatic metastasis.

Conclusions:

• Sentinel lymph node mapping is an increasingly integrated and valuable tool in managing early-stage gynecologic cancers.
• SLN mapping offers a balance between minimizing surgical morbidity and ensuring accurate lymphatic staging.
• Further clinical trials are essential to refine SLN mapping techniques and expand its application in gynecologic oncology.